Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
Minor
Trial sites expanded: 42 → 51 locations
Minor
Site contacts updated at 1 of 42 sites
Minor
Trial sites expanded: 29 → 42 locations
Minor
Trial sites expanded: 17 → 29 locations
- Site details revised at 17 of 29 sites
Minor
Study sites: 17 to 29
Notable
Eligibility criteria expanded, about 9 words
- Trial sites expanded: 12 → 17 locations
- Secondary endpoints: details revised at 6 of 23 entries
Minor
Trial sites expanded: 7 → 12 locations
- Secondary endpoints: 21 to 23
v3
Notable
Recruitment opened
- Trial sites expanded: 0 → 7 locations
- Start date changed from estimate of Jun 2026 to Jun 10, 2026
v2
Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Timeframe: up to 24 weeks (part A)
Secondary (23)
Time to becoming euthyroid off ATDs in part A
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Time to becoming euthyroid off ATDs and TRAb seronegative
Show 18 moreShow less
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Time to becoming euthyroid
Time to having fT3 and fT4 levels within normal ranges among participants who had fT3 and/or fT4 more than the ULN at baseline (part A)
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Percentage of participants who remain euthyroid off ATDs
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day
Percentage of participants who remain euthyroid without ATDs
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Incidence of AEs and SAEs
Change in ThyPRO-39 over time
Change in PROMIS-PF10a over time
Efgartigimod serum concentrations over time
Percentage change from baseline in total IgG levels in serum over time
Percentage change from baseline in TRAb serum levels over time
Incidence of ADA against efgartigimod in serum
Incidence of antibodies against rHuPH20 in plasma
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Arms and interventions
Part A - efgartigimod PH20 SC PFSExperimental
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Part A - placebo PH20 SC PFSPlacebo comparator
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Part B - efgartigimod PH20 SC PFSExperimental
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Part B - placebo PH20 SC PFSExperimental
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Part C - efgartigimod PH20 SC PFSExperimental
Participants, will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
Biologicals: efgartigimod PH20 SC
Other: Placebo PH20 SC
Sites
51 sites in 14 countries
Japan 11, Poland 10, Bulgaria 7, Spain 5, Georgia 3, Belgium 2, Canada 2, Greece 2, Latvia 2, Lithuania 2, Romania 2, Denmark 1, Germany 1, Italy 1